<rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom" xmlns:content="http://purl.org/rss/1.0/modules/content/" xmlns:dc="http://purl.org/dc/elements/1.1/">
<channel>
<title>心血管高分期刊</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/rss-feed/?feed_id=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;utm_source=Chrome&amp;fc=20230708114047&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;v=2.18.0&amp;utm_campaign=pubmed-2&amp;ff=20240127211631&amp;utm_medium=rss
    <description>心血管高分期刊: Latest results from PubMed</description>
<atom:link href="https://pubmed.ncbi.nlm.nih.gov/rss-feed/?feed_id=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;utm_source=Chrome&amp;fc=20230708114047&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;v=2.18.0&amp;utm_campaign=pubmed-2&amp;ff=20240127211631&amp;utm_medium=rss" rel="self"></atom:link>
<docs>http://www.rssboard.org/rss-specification</docs>
<generator>PubMed RSS feeds (2.18.0)</generator>
<language>en</language>
<lastbuilddate>Sun, 28 Jan 2024 02:16:32 +0000</lastbuilddate>
<pubDate>Fri, 26 Jan 2024 06:00:00 -0500</pubDate>
<ttl>120</ttl>
<item>
<title>Reply to 'Graded exercise therapy should not be recommended for patients with post-exertional malaise'</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38279048/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240127211631&amp;v=2.18.0
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Nat Rev Cardiol. 2024 Jan 26. doi: 10.1038/s41569-024-00994-3. Online ahead of print.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38279048/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240127211631&v=2.18.0">38279048</a> | DOI:<a href=https://doi.org/10.1038/s41569-024-00994-3>10.1038/s41569-024-00994-3</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38279048</guid>
<pubDate>Fri, 26 Jan 2024 06:00:00 -0500</pubDate>
<dc:creator>Artur Fedorowski</dc:creator>
<dc:creator>Alessandra Fanciulli</dc:creator>
<dc:creator>Satish R Raj</dc:creator>
<dc:creator>Robert Sheldon</dc:creator>
<dc:creator>Cyndya A Shibao</dc:creator>
<dc:creator>Richard Sutton</dc:creator>
<dc:date>2024-01-26</dc:date>
<dc:source>Nature reviews. Cardiology</dc:source>
<dc:title>Reply to 'Graded exercise therapy should not be recommended for patients with post-exertional malaise'</dc:title>
<dc:identifier>pmid:38279048</dc:identifier>
<dc:identifier>doi:10.1038/s41569-024-00994-3</dc:identifier>
</item>
<item>
<title>Graded exercise therapy should not be recommended for patients with post-exertional malaise</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38279047/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240127211631&amp;v=2.18.0
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Nat Rev Cardiol. 2024 Jan 26. doi: 10.1038/s41569-024-00992-5. Online ahead of print.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38279047/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240127211631&v=2.18.0">38279047</a> | DOI:<a href=https://doi.org/10.1038/s41569-024-00992-5>10.1038/s41569-024-00992-5</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38279047</guid>
<pubDate>Fri, 26 Jan 2024 06:00:00 -0500</pubDate>
<dc:creator>Femke Christina Ching-Chuan van Rhijn-Brouwer</dc:creator>
<dc:creator>Merel Hellemons</dc:creator>
<dc:creator>Michael Stingl</dc:creator>
<dc:creator>Kathryn Hoffmann</dc:creator>
<dc:creator>Joanne VanDerNagel</dc:creator>
<dc:creator>Todd E Davenport</dc:creator>
<dc:creator>Eva Untersmayr</dc:creator>
<dc:creator>Carmen Scheibenbogen</dc:creator>
<dc:creator>David Putrino</dc:creator>
<dc:date>2024-01-26</dc:date>
<dc:source>Nature reviews. Cardiology</dc:source>
<dc:title>Graded exercise therapy should not be recommended for patients with post-exertional malaise</dc:title>
<dc:identifier>pmid:38279047</dc:identifier>
<dc:identifier>doi:10.1038/s41569-024-00992-5</dc:identifier>
</item>
<item>
<title>Immune checkpoints in cardiac physiology and pathology: therapeutic targets for heart failure</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38279046/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240127211631&amp;v=2.18.0
      <description>Immune checkpoint molecules are physiological regulators of the adaptive immune response. Immune checkpoint inhibitors (ICIs), such as monoclonal antibodies targeting programmed cell death protein 1 or cytotoxic T lymphocyte-associated protein 4, have revolutionized cancer treatment and their clinical use is increasing. However, ICIs can cause various immune-related adverse events, including acute and chronic cardiotoxicity. Of these cardiovascular complications, ICI-induced acute fulminant...</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Nat Rev Cardiol. 2024 Jan 26. doi: 10.1038/s41569-023-00986-9. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">Immune checkpoint molecules are physiological regulators of the adaptive immune response. Immune checkpoint inhibitors (ICIs), such as monoclonal antibodies targeting programmed cell death protein 1 or cytotoxic T lymphocyte-associated protein 4, have revolutionized cancer treatment and their clinical use is increasing. However, ICIs can cause various immune-related adverse events, including acute and chronic cardiotoxicity. Of these cardiovascular complications, ICI-induced acute fulminant myocarditis is the most studied, although emerging clinical and preclinical data are uncovering the importance of other ICI-related chronic cardiovascular complications, such as accelerated atherosclerosis and non-myocarditis-related heart failure. These complications could be more difficult to diagnose, given that they might only be present alongside other comorbidities. The occurrence of these complications suggests a potential role of immune checkpoint molecules in maintaining cardiovascular homeostasis, and disruption of physiological immune checkpoint signalling might thus lead to cardiac pathologies, including heart failure. Although inflammation is a long-known contributor to the development of heart failure, the therapeutic targeting of pro-inflammatory pathways has not been successful thus far. The increasingly recognized role of immune checkpoint molecules in the failing heart highlights their potential use as immunotherapeutic targets for heart failure. In this Review, we summarize the available data on ICI-induced cardiac dysfunction and heart failure, and discuss how immune checkpoint signalling is altered in the failing heart. Furthermore, we describe how pharmacological targeting of immune checkpoints could be used to treat heart failure.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38279046/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240127211631&v=2.18.0">38279046</a> | DOI:<a href=https://doi.org/10.1038/s41569-023-00986-9>10.1038/s41569-023-00986-9</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38279046</guid>
<pubDate>Fri, 26 Jan 2024 06:00:00 -0500</pubDate>
<dc:creator>Tamás G Gergely</dc:creator>
<dc:creator>Zsófia D Drobni</dc:creator>
<dc:creator>Marinos Kallikourdis</dc:creator>
<dc:creator>Han Zhu</dc:creator>
<dc:creator>Wouter C Meijers</dc:creator>
<dc:creator>Tomas G Neilan</dc:creator>
<dc:creator>Tienush Rassaf</dc:creator>
<dc:creator>Péter Ferdinandy</dc:creator>
<dc:creator>Zoltán V Varga</dc:creator>
<dc:date>2024-01-26</dc:date>
<dc:source>Nature reviews. Cardiology</dc:source>
<dc:title>Immune checkpoints in cardiac physiology and pathology: therapeutic targets for heart failure</dc:title>
<dc:identifier>pmid:38279046</dc:identifier>
<dc:identifier>doi:10.1038/s41569-023-00986-9</dc:identifier>
</item>
<item>
<title>Protein Kinase A Is a Master Regulator of Physiological and Pathological Cardiac Hypertrophy</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38275112/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240127211631&amp;v=2.18.0
      <description>CONCLUSIONS: Cardiomyocyte PKA is a master regulator of physiological CH and PaCH through regulating protein synthesis and degradation. cPKAi can be a novel approach to treat PaCH.</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Circ Res. 2024 Jan 26. doi: 10.1161/CIRCRESAHA.123.322729. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">BACKGROUND: The sympathoadrenergic system and its major effector PKA (protein kinase A) are activated to maintain cardiac output coping with physiological or pathological stressors. If and how PKA plays a role in physiological cardiac hypertrophy (CH) and pathological CH (PaCH) are not clear.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">METHODS: Transgenic mouse models expressing a PKA inhibition peptide-GFP fusion protein in a cardiac-specific and inducible manner (cPKAi) were used to determine the roles of PKA in physiological CH during postnatal growth or induced by swimming, and in PaCH induced by transaortic constriction (TAC) or augmented Ca<sup>2+</sup> influx. Kinase profiling was used to determine cPKAi specificity. Echocardiography was used to determine cardiac morphology and function. Western blotting and immunostaining were used to measure protein abundance and phosphorylation. Protein synthesis was assessed by puromycin incorporation and protein degradation by measuring protein ubiquitination and proteasome activity. Neonatal rat cardiomyocytes (NRCMs) infected with AdGFP or AdPKAi-GFP were used to determine the effects and mechanisms of cPKAi on myocyte hypertrophy. rAAV9.PKA inhibition peptide-GFP was used to treat TAC mice.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">RESULTS: (1) cPKAi delayed postnatal cardiac growth and blunted exercise-induced physiological CH; (2) PKA was activated in hearts after TAC due to activated sympathoadrenergic system, the loss of endogenous PKIα (PKA inhibitory peptide α), and the stimulation by noncanonical PKA activators; (3) cPKAi ameliorated PaCH induced by TAC and increased Ca<sup>2+</sup> influxes and blunted neonatal rat cardiomyocyte hypertrophy by isoproterenol and phenylephrine; (4) cPKAi prevented TAC-induced protein synthesis by inhibiting mTOR signaling through reducing Akt activity, but enhancing inhibitory GSK-3α and GSK-3β signals; (5) cPKAi reduced protein degradation by the ubiquitin-proteasome system via decreasing RPN6 phosphorylation; (6) cPKAi increased the expression of antihypertrophic ANP; (7) cPKAi ameliorated established PaCH and improved animal survival.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">CONCLUSIONS: Cardiomyocyte PKA is a master regulator of physiological CH and PaCH through regulating protein synthesis and degradation. cPKAi can be a novel approach to treat PaCH.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38275112/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240127211631&v=2.18.0">38275112</a> | DOI:<a href=https://doi.org/10.1161/CIRCRESAHA.123.322729>10.1161/CIRCRESAHA.123.322729</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38275112</guid>
<pubDate>Fri, 26 Jan 2024 06:00:00 -0500</pubDate>
<dc:creator>Yingyu Bai</dc:creator>
<dc:creator>Xiaoying Zhang</dc:creator>
<dc:creator>Ying Li</dc:creator>
<dc:creator>Fei Qi</dc:creator>
<dc:creator>Chong Liu</dc:creator>
<dc:creator>Xiaojie Ai</dc:creator>
<dc:creator>Mingxin Tang</dc:creator>
<dc:creator>Christopher Szeto</dc:creator>
<dc:creator>Erhe Gao</dc:creator>
<dc:creator>Xiang Hua</dc:creator>
<dc:creator>Mingxing Xie</dc:creator>
<dc:creator>Xuejun Wang</dc:creator>
<dc:creator>Ying Tian</dc:creator>
<dc:creator>Yongjie Chen</dc:creator>
<dc:creator>Guowei Huang</dc:creator>
<dc:creator>Junping Zhang</dc:creator>
<dc:creator>Weidong Xiao</dc:creator>
<dc:creator>Lili Zhang</dc:creator>
<dc:creator>Xueyuan Liu</dc:creator>
<dc:creator>Qing Yang</dc:creator>
<dc:creator>Steven R Houser</dc:creator>
<dc:creator>Xiongwen Chen</dc:creator>
<dc:date>2024-01-26</dc:date>
<dc:source>Circulation research</dc:source>
<dc:title>Protein Kinase A Is a Master Regulator of Physiological and Pathological Cardiac Hypertrophy</dc:title>
<dc:identifier>pmid:38275112</dc:identifier>
<dc:identifier>doi:10.1161/CIRCRESAHA.123.322729</dc:identifier>
</item>
<item>
<title>Myocardial Scar and Remodelling Predict Long-Term Mortality in Severe Aortic Stenosis Beyond 10 Years</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38271583/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240127211631&amp;v=2.18.0
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Eur Heart J. 2024 Jan 25:ehae067. doi: 10.1093/eurheartj/ehae067. Online ahead of print.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38271583/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240127211631&v=2.18.0">38271583</a> | DOI:<a href=https://doi.org/10.1093/eurheartj/ehae067>10.1093/eurheartj/ehae067</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38271583</guid>
<pubDate>Thu, 25 Jan 2024 06:00:00 -0500</pubDate>
<dc:creator>George D Thornton</dc:creator>
<dc:creator>Vassilios S Vassiliou</dc:creator>
<dc:creator>Tarique A Musa</dc:creator>
<dc:creator>Nikoo Aziminia</dc:creator>
<dc:creator>Neil Craig</dc:creator>
<dc:creator>Abhishek Dattani</dc:creator>
<dc:creator>Rhodri H Davies</dc:creator>
<dc:creator>Gabriella Captur</dc:creator>
<dc:creator>James C Moon</dc:creator>
<dc:creator>Marc R Dweck</dc:creator>
<dc:creator>Saul G Myerson</dc:creator>
<dc:creator>Sanjay K Prasad</dc:creator>
<dc:creator>Gerry P McCann</dc:creator>
<dc:creator>BSCMR AS700 Consortium</dc:creator>
<dc:creator>John P Greenwood</dc:creator>
<dc:creator>Anvesha Singh</dc:creator>
<dc:creator>Thomas A Treibel</dc:creator>
<dc:date>2024-01-25</dc:date>
<dc:source>European heart journal</dc:source>
<dc:title>Myocardial Scar and Remodelling Predict Long-Term Mortality in Severe Aortic Stenosis Beyond 10 Years</dc:title>
<dc:identifier>pmid:38271583</dc:identifier>
<dc:identifier>doi:10.1093/eurheartj/ehae067</dc:identifier>
</item>
<item>
<title>'Training' of innate immunity following myocardial infarction exacerbates atherosclerosis</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38271239/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240127211631&amp;v=2.18.0
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Eur Heart J. 2024 Jan 25:ehae024. doi: 10.1093/eurheartj/ehae024. Online ahead of print.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38271239/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240127211631&v=2.18.0">38271239</a> | DOI:<a href=https://doi.org/10.1093/eurheartj/ehae024>10.1093/eurheartj/ehae024</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38271239</guid>
<pubDate>Thu, 25 Jan 2024 06:00:00 -0500</pubDate>
<dc:creator>Niranjana Natarajan</dc:creator>
<dc:creator>Partha Dutta</dc:creator>
<dc:date>2024-01-25</dc:date>
<dc:source>European heart journal</dc:source>
<dc:title>'Training' of innate immunity following myocardial infarction exacerbates atherosclerosis</dc:title>
<dc:identifier>pmid:38271239</dc:identifier>
<dc:identifier>doi:10.1093/eurheartj/ehae024</dc:identifier>
</item>
<item>
<title>Pre-operative withdrawal of renin-angiotensin inhibitors: time to re-visit current guidelines</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38271231/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240127211631&amp;v=2.18.0
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Eur Heart J. 2024 Jan 25:ehad719. doi: 10.1093/eurheartj/ehad719. Online ahead of print.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38271231/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240127211631&v=2.18.0">38271231</a> | DOI:<a href=https://doi.org/10.1093/eurheartj/ehad719>10.1093/eurheartj/ehad719</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38271231</guid>
<pubDate>Thu, 25 Jan 2024 06:00:00 -0500</pubDate>
<dc:creator>W Scott Beattie</dc:creator>
<dc:date>2024-01-25</dc:date>
<dc:source>European heart journal</dc:source>
<dc:title>Pre-operative withdrawal of renin-angiotensin inhibitors: time to re-visit current guidelines</dc:title>
<dc:identifier>pmid:38271231</dc:identifier>
<dc:identifier>doi:10.1093/eurheartj/ehad719</dc:identifier>
</item>
<item>
<title>A collateral channel from the bronchial artery in chronic total occlusion of proximal right coronary artery</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38270256/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240127211631&amp;v=2.18.0
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Eur Heart J. 2024 Jan 25:ehae036. doi: 10.1093/eurheartj/ehae036. Online ahead of print.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38270256/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240127211631&v=2.18.0">38270256</a> | DOI:<a href=https://doi.org/10.1093/eurheartj/ehae036>10.1093/eurheartj/ehae036</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38270256</guid>
<pubDate>Thu, 25 Jan 2024 06:00:00 -0500</pubDate>
<dc:creator>Kosuke Tsuda</dc:creator>
<dc:creator>Wataru Nagamatsu</dc:creator>
<dc:creator>Isao Morii</dc:creator>
<dc:date>2024-01-25</dc:date>
<dc:source>European heart journal</dc:source>
<dc:title>A collateral channel from the bronchial artery in chronic total occlusion of proximal right coronary artery</dc:title>
<dc:identifier>pmid:38270256</dc:identifier>
<dc:identifier>doi:10.1093/eurheartj/ehae036</dc:identifier>
</item>
<item>
<title>Critical 11 min in contrast-enhanced computed tomography for acute aortic dissection</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38270254/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240127211631&amp;v=2.18.0
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Eur Heart J. 2024 Jan 25:ehae037. doi: 10.1093/eurheartj/ehae037. Online ahead of print.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38270254/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240127211631&v=2.18.0">38270254</a> | DOI:<a href=https://doi.org/10.1093/eurheartj/ehae037>10.1093/eurheartj/ehae037</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38270254</guid>
<pubDate>Thu, 25 Jan 2024 06:00:00 -0500</pubDate>
<dc:creator>Yusuke Iguchi</dc:creator>
<dc:creator>Arudo Hiraoka</dc:creator>
<dc:creator>Genta Chikazawa</dc:creator>
<dc:date>2024-01-25</dc:date>
<dc:source>European heart journal</dc:source>
<dc:title>Critical 11 min in contrast-enhanced computed tomography for acute aortic dissection</dc:title>
<dc:identifier>pmid:38270254</dc:identifier>
<dc:identifier>doi:10.1093/eurheartj/ehae037</dc:identifier>
</item>
<item>
<title>Increasing cardiovascular hospitalization rates among young and middle-aged adults in the USA suggest a need for multi-faceted solutions</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38270197/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240127211631&amp;v=2.18.0
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Eur Heart J. 2024 Jan 25:ehae027. doi: 10.1093/eurheartj/ehae027. Online ahead of print.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38270197/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240127211631&v=2.18.0">38270197</a> | DOI:<a href=https://doi.org/10.1093/eurheartj/ehae027>10.1093/eurheartj/ehae027</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38270197</guid>
<pubDate>Thu, 25 Jan 2024 06:00:00 -0500</pubDate>
<dc:creator>Samantha T Harris</dc:creator>
<dc:creator>Karen E Joynt Maddox</dc:creator>
<dc:date>2024-01-25</dc:date>
<dc:source>European heart journal</dc:source>
<dc:title>Increasing cardiovascular hospitalization rates among young and middle-aged adults in the USA suggest a need for multi-faceted solutions</dc:title>
<dc:identifier>pmid:38270197</dc:identifier>
<dc:identifier>doi:10.1093/eurheartj/ehae027</dc:identifier>
</item>
<item>
<title>Impact of untreated chronic obstructive coronary artery disease on outcomes after transcatheter aortic valve replacement</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38270189/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240127211631&amp;v=2.18.0
      <description>CONCLUSIONS: Transcatheter aortic valve replacement can be performed safely in patients with untreated chronic obstructive CAD, without portending higher procedural complication rates and with relatively low rates of unplanned coronary revascularization and acute coronary syndrome at 1 year.</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Eur Heart J. 2024 Jan 25:ehae019. doi: 10.1093/eurheartj/ehae019. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">BACKGROUND AND AIMS: In transcatheter aortic valve replacement (TAVR) recipients, the optimal management of concomitant chronic obstructive coronary artery disease (CAD) remains unknown. Some advocate for pre-TAVR percutaneous coronary intervention, while others manage it expectantly. The aim of this study was to assess the impact of varying degrees and extent of untreated chronic obstructive CAD on TAVR and longer-term outcomes.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">METHODS: The authors conducted a retrospective cohort study of TAVR recipients from January 2015 to November 2021, separating patients into stable non-obstructive or varying degrees of obstructive CAD. The major outcomes of interest were procedural all-cause mortality and complications, major adverse cardiovascular events, and post-TAVR unplanned coronary revascularization.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">RESULTS: Of the 1911 patients meeting inclusion, 75%, 6%, 10%, and 9% had non-obstructive, intermediate-risk, high-risk, and extreme-risk CAD, respectively. Procedural complication rates overall were low (death 0.4%, shock 0.1%, extracorporeal membrane oxygenation 0.1%), with no difference across groups. At a median follow-up of 21 months, rates of acute coronary syndrome and unplanned coronary revascularization were 0.7% and 0.5%, respectively, in the non-obstructive population, rising in incidence with increasing severity of CAD (P &lt; .001 for acute coronary syndrome/unplanned coronary revascularization). Multivariable analysis did not yield a significantly greater risk of all-cause mortality or major adverse cardiovascular events across groups. One-year acute coronary syndrome and unplanned coronary revascularization rates in time-to-event analyses were significantly greater in the non-obstructive (98%) vs. obstructive (94%) subsets (Plog-rank&lt; .001).</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">CONCLUSIONS: Transcatheter aortic valve replacement can be performed safely in patients with untreated chronic obstructive CAD, without portending higher procedural complication rates and with relatively low rates of unplanned coronary revascularization and acute coronary syndrome at 1 year.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38270189/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240127211631&v=2.18.0">38270189</a> | DOI:<a href=https://doi.org/10.1093/eurheartj/ehae019>10.1093/eurheartj/ehae019</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38270189</guid>
<pubDate>Thu, 25 Jan 2024 06:00:00 -0500</pubDate>
<dc:creator>Ian Persits</dc:creator>
<dc:creator>Habib Layoun</dc:creator>
<dc:creator>Nicholas P Kondoleon</dc:creator>
<dc:creator>Nikolaos Spilias</dc:creator>
<dc:creator>Osamah Badwan</dc:creator>
<dc:creator>Joseph Sipko</dc:creator>
<dc:creator>James J Yun</dc:creator>
<dc:creator>Ankur Kalra</dc:creator>
<dc:creator>Iryna Dykun</dc:creator>
<dc:creator>Larisa G Tereshchenko</dc:creator>
<dc:creator>Amar Krishnaswamy</dc:creator>
<dc:creator>Grant W Reed</dc:creator>
<dc:creator>Samir R Kapadia</dc:creator>
<dc:creator>Rishi Puri</dc:creator>
<dc:date>2024-01-25</dc:date>
<dc:source>European heart journal</dc:source>
<dc:title>Impact of untreated chronic obstructive coronary artery disease on outcomes after transcatheter aortic valve replacement</dc:title>
<dc:identifier>pmid:38270189</dc:identifier>
<dc:identifier>doi:10.1093/eurheartj/ehae019</dc:identifier>
</item>
<item>
<title>Deciphering connections: how is cryoablation interlinking with disease progression in atrial fibrillation ablation?</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38267267/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240127211631&amp;v=2.18.0
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Eur Heart J. 2024 Jan 24:ehad872. doi: 10.1093/eurheartj/ehad872. Online ahead of print.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38267267/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240127211631&v=2.18.0">38267267</a> | DOI:<a href=https://doi.org/10.1093/eurheartj/ehad872>10.1093/eurheartj/ehad872</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38267267</guid>
<pubDate>Wed, 24 Jan 2024 06:00:00 -0500</pubDate>
<dc:creator>Hadi Younes</dc:creator>
<dc:creator>Swati Rao</dc:creator>
<dc:creator>Nassir Marrouche</dc:creator>
<dc:date>2024-01-24</dc:date>
<dc:source>European heart journal</dc:source>
<dc:title>Deciphering connections: how is cryoablation interlinking with disease progression in atrial fibrillation ablation?</dc:title>
<dc:identifier>pmid:38267267</dc:identifier>
<dc:identifier>doi:10.1093/eurheartj/ehad872</dc:identifier>
</item>
<item>
<title>REPLY: Interpreting the Impact of Complete Revascularization in the ISCHEMIA Trial</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38267120/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240127211631&amp;v=2.18.0
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">J Am Coll Cardiol. 2024 Jan 30;83(4):e39-e40. doi: 10.1016/j.jacc.2023.11.018.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38267120/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240127211631&v=2.18.0">38267120</a> | DOI:<a href=https://doi.org/10.1016/j.jacc.2023.11.018>10.1016/j.jacc.2023.11.018</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38267120</guid>
<pubDate>Wed, 24 Jan 2024 06:00:00 -0500</pubDate>
<dc:creator>Gregg W Stone</dc:creator>
<dc:creator>Ziad A Ali</dc:creator>
<dc:creator>Judith S Hochman</dc:creator>
<dc:creator>David J Maron</dc:creator>
<dc:date>2024-01-24</dc:date>
<dc:source>Journal of the American College of Cardiology</dc:source>
<dc:title>REPLY: Interpreting the Impact of Complete Revascularization in the ISCHEMIA Trial</dc:title>
<dc:identifier>pmid:38267120</dc:identifier>
<dc:identifier>doi:10.1016/j.jacc.2023.11.018</dc:identifier>
</item>
<item>
<title>Benefit of Complete Anatomic Revascularization in ISCHEMIA: Reprise of a Familiar Theme</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38267119/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240127211631&amp;v=2.18.0
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">J Am Coll Cardiol. 2024 Jan 30;83(4):e37. doi: 10.1016/j.jacc.2023.10.047.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38267119/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240127211631&v=2.18.0">38267119</a> | DOI:<a href=https://doi.org/10.1016/j.jacc.2023.10.047>10.1016/j.jacc.2023.10.047</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38267119</guid>
<pubDate>Wed, 24 Jan 2024 06:00:00 -0500</pubDate>
<dc:creator>Robert A Guyton</dc:creator>
<dc:creator>Michael E Halkos</dc:creator>
<dc:date>2024-01-24</dc:date>
<dc:source>Journal of the American College of Cardiology</dc:source>
<dc:title>Benefit of Complete Anatomic Revascularization in ISCHEMIA: Reprise of a Familiar Theme</dc:title>
<dc:identifier>pmid:38267119</dc:identifier>
<dc:identifier>doi:10.1016/j.jacc.2023.10.047</dc:identifier>
</item>
<item>
<title>Functional vs Anatomical Complete Revascularization: Is There an "ISCHEMIA" of FFR?</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38267118/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240127211631&amp;v=2.18.0
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">J Am Coll Cardiol. 2024 Jan 30;83(4):e35. doi: 10.1016/j.jacc.2023.10.048.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38267118/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240127211631&v=2.18.0">38267118</a> | DOI:<a href=https://doi.org/10.1016/j.jacc.2023.10.048>10.1016/j.jacc.2023.10.048</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38267118</guid>
<pubDate>Wed, 24 Jan 2024 06:00:00 -0500</pubDate>
<dc:creator>Kyriakos Dimitriadis</dc:creator>
<dc:creator>Nikolaos Pyrpyris</dc:creator>
<dc:creator>Konstantinos Tsioufis</dc:creator>
<dc:date>2024-01-24</dc:date>
<dc:source>Journal of the American College of Cardiology</dc:source>
<dc:title>Functional vs Anatomical Complete Revascularization: Is There an "ISCHEMIA" of FFR?</dc:title>
<dc:identifier>pmid:38267118</dc:identifier>
<dc:identifier>doi:10.1016/j.jacc.2023.10.048</dc:identifier>
</item>
<item>
<title>And Yet it Moves: E Pur Si Muove</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38267117/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240127211631&amp;v=2.18.0
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">J Am Coll Cardiol. 2024 Jan 30;83(4):e33. doi: 10.1016/j.jacc.2023.10.049.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38267117/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240127211631&v=2.18.0">38267117</a> | DOI:<a href=https://doi.org/10.1016/j.jacc.2023.10.049>10.1016/j.jacc.2023.10.049</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38267117</guid>
<pubDate>Wed, 24 Jan 2024 06:00:00 -0500</pubDate>
<dc:creator>Victor Dayan</dc:creator>
<dc:creator>Rafael Sadaba</dc:creator>
<dc:creator>Patrick Myers</dc:creator>
<dc:creator>Joe Sabik</dc:creator>
<dc:creator>Faisal Bakeen</dc:creator>
<dc:date>2024-01-24</dc:date>
<dc:source>Journal of the American College of Cardiology</dc:source>
<dc:title>And Yet it Moves: E Pur Si Muove</dc:title>
<dc:identifier>pmid:38267117</dc:identifier>
<dc:identifier>doi:10.1016/j.jacc.2023.10.049</dc:identifier>
</item>
<item>
<title>Drawing Conclusions From Exploratory Analyses: A Slippery Slope</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38267116/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240127211631&amp;v=2.18.0
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">J Am Coll Cardiol. 2024 Jan 30;83(4):e31. doi: 10.1016/j.jacc.2023.10.050.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38267116/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240127211631&v=2.18.0">38267116</a> | DOI:<a href=https://doi.org/10.1016/j.jacc.2023.10.050>10.1016/j.jacc.2023.10.050</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38267116</guid>
<pubDate>Wed, 24 Jan 2024 06:00:00 -0500</pubDate>
<dc:creator>Sanjay Kaul</dc:creator>
<dc:creator>G B John Mancini</dc:creator>
<dc:creator>William S Weintraub</dc:creator>
<dc:creator>Raffaele De Caterina</dc:creator>
<dc:creator>INTEGRITTY</dc:creator>
<dc:date>2024-01-24</dc:date>
<dc:source>Journal of the American College of Cardiology</dc:source>
<dc:title>Drawing Conclusions From Exploratory Analyses: A Slippery Slope</dc:title>
<dc:identifier>pmid:38267116</dc:identifier>
<dc:identifier>doi:10.1016/j.jacc.2023.10.050</dc:identifier>
</item>
<item>
<title>Predictors of Repeated Septal Reduction After Alcohol Septal Ablation in Patients With Hypertrophic Cardiomyopathy</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38267115/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240127211631&amp;v=2.18.0
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">J Am Coll Cardiol. 2024 Jan 30;83(4):546-548. doi: 10.1016/j.jacc.2023.11.013.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38267115/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240127211631&v=2.18.0">38267115</a> | DOI:<a href=https://doi.org/10.1016/j.jacc.2023.11.013>10.1016/j.jacc.2023.11.013</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38267115</guid>
<pubDate>Wed, 24 Jan 2024 06:00:00 -0500</pubDate>
<dc:creator>Takashi Hiruma</dc:creator>
<dc:creator>Mitsunobu Kitamura</dc:creator>
<dc:creator>Itaru Takamisawa</dc:creator>
<dc:creator>Yuki Izumi</dc:creator>
<dc:creator>Ryosuke Higuchi</dc:creator>
<dc:creator>Mamoru Nanasato</dc:creator>
<dc:creator>Tomoki Shimokawa</dc:creator>
<dc:creator>Shuichiro Takanashi</dc:creator>
<dc:creator>Mitsuaki Isobe</dc:creator>
<dc:creator>Morimasa Takayama</dc:creator>
<dc:date>2024-01-24</dc:date>
<dc:source>Journal of the American College of Cardiology</dc:source>
<dc:title>Predictors of Repeated Septal Reduction After Alcohol Septal Ablation in Patients With Hypertrophic Cardiomyopathy</dc:title>
<dc:identifier>pmid:38267115</dc:identifier>
<dc:identifier>doi:10.1016/j.jacc.2023.11.013</dc:identifier>
</item>
<item>
<title>Racial and Ethnic Disparities in Perioperative Health Care Among Patients Undergoing Cardiac Surgery: JACC State-of-the-Art Review</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38267114/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240127211631&amp;v=2.18.0
      <description>There has been little progress in reducing health care disparities since the 2003 landmark Institute of Medicine's report Unequal Treatment. Despite the higher burden of cardiovascular disease in underrepresented racial and ethnic groups, they have less access to cardiologists and cardiothoracic surgeons, and have higher rates of morbidity and mortality with cardiac surgical interventions. This review summarizes existing literature and highlights disparities in cardiovascular perioperative...</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">J Am Coll Cardiol. 2024 Jan 30;83(4):530-545. doi: 10.1016/j.jacc.2023.11.015.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">There has been little progress in reducing health care disparities since the 2003 landmark Institute of Medicine's report Unequal Treatment. Despite the higher burden of cardiovascular disease in underrepresented racial and ethnic groups, they have less access to cardiologists and cardiothoracic surgeons, and have higher rates of morbidity and mortality with cardiac surgical interventions. This review summarizes existing literature and highlights disparities in cardiovascular perioperative health care. We propose actionable solutions utilizing multidisciplinary perspectives from cardiology, cardiac surgery, cardiothoracic anesthesiology, critical care, medical ethics, and health disparity experts. Applying a health equity lens to multipronged interventions is necessary to eliminate the disparities in perioperative health care among patients undergoing cardiac surgery.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38267114/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240127211631&v=2.18.0">38267114</a> | DOI:<a href=https://doi.org/10.1016/j.jacc.2023.11.015>10.1016/j.jacc.2023.11.015</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38267114</guid>
<pubDate>Wed, 24 Jan 2024 06:00:00 -0500</pubDate>
<dc:creator>Adam J Milam</dc:creator>
<dc:creator>Modele O Ogunniyi</dc:creator>
<dc:creator>Abimbola O Faloye</dc:creator>
<dc:creator>Luis R Castellanos</dc:creator>
<dc:creator>Ricardo E Verdiner</dc:creator>
<dc:creator>James W Stewart</dc:creator>
<dc:creator>Merije Chukumerije</dc:creator>
<dc:creator>Alexis K Okoh</dc:creator>
<dc:creator>Steven Bradley</dc:creator>
<dc:creator>Robert O Roswell</dc:creator>
<dc:creator>Paul L Douglass</dc:creator>
<dc:creator>Shakirat O Oyetunji</dc:creator>
<dc:creator>Alexander Iribarne</dc:creator>
<dc:creator>Debra Furr-Holden</dc:creator>
<dc:creator>Harish Ramakrishna</dc:creator>
<dc:creator>Sharonne N Hayes</dc:creator>
<dc:date>2024-01-24</dc:date>
<dc:source>Journal of the American College of Cardiology</dc:source>
<dc:title>Racial and Ethnic Disparities in Perioperative Health Care Among Patients Undergoing Cardiac Surgery: JACC State-of-the-Art Review</dc:title>
<dc:identifier>pmid:38267114</dc:identifier>
<dc:identifier>doi:10.1016/j.jacc.2023.11.015</dc:identifier>
</item>
<item>
<title>Role of Initial Focal Contrast Enhancement in Type B Intramural Hematoma</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38267113/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240127211631&amp;v=2.18.0
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">J Am Coll Cardiol. 2024 Jan 30;83(4):514-515. doi: 10.1016/j.jacc.2023.11.017.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38267113/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240127211631&v=2.18.0">38267113</a> | DOI:<a href=https://doi.org/10.1016/j.jacc.2023.11.017>10.1016/j.jacc.2023.11.017</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38267113</guid>
<pubDate>Wed, 24 Jan 2024 06:00:00 -0500</pubDate>
<dc:creator>Konstantinos Spanos</dc:creator>
<dc:creator>Tilo Kölbel</dc:creator>
<dc:date>2024-01-24</dc:date>
<dc:source>Journal of the American College of Cardiology</dc:source>
<dc:title>Role of Initial Focal Contrast Enhancement in Type B Intramural Hematoma</dc:title>
<dc:identifier>pmid:38267113</dc:identifier>
<dc:identifier>doi:10.1016/j.jacc.2023.11.017</dc:identifier>
</item>
<item>
<title>Prognostic Implications of Initial Focal Contrast Enhancement in Acute Type B Intramural Hematoma</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38267112/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240127211631&amp;v=2.18.0
      <description>CONCLUSIONS: Patients with FCE accompanying IMH were more likely to progress, especially in those initial FID localized at the proximal descending aorta. (Nature course and predictors of progression of intramural hematoma: A retrospective, multicenter study; ChiCTR2300073829).</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">J Am Coll Cardiol. 2024 Jan 30;83(4):503-513. doi: 10.1016/j.jacc.2023.10.046.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">BACKGROUND: The prognostic implication of initial focal contrast enhancement (FCE), including focal intimal disruption (FID) and intramural blood pool (IBP), in acute type B intramural hematoma (IMH) remain unclear.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">OBJECTIVES: The purpose of this study was to compare the prognostic implications in IMH with or without FCE.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">METHODS: A total of 574 patients were enrolled. FID was defined as an intimal disruption with contrast-filled out-pouching from the aorta lumen with a communicating orifice of >;3 mm, and IBP was defined as a localized contrast medium-filled pool inside the IMH.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">RESULTS: A total of 207 (36.1%) patients with initial FCE, including 132 (63.8%) FIDs and 75 (36.2%) IBPs, were identified. Patients with FCE accompanying IMH were more likely to have hypertension (P = 0.001), pleural effusion (P = 0.006), fewer aortic segments involved (P &lt; 0.001), more adverse aortic events (AAEs) (P &lt; 0.001), and fewer freedom from intervention (P = 0.002). Pleural effusion (HR: 1.79; 95% CI: 1.25-2.55; P = 0.001) and FCE (HR: 1.51; 95% CI: 1.12-2.02; P = 0.006) were identified to be the independent risk factors of AAEs. In the subgroup analysis, IMH with initial FID were more likely to progress than those with initial IBP (P &lt; 0.001). FIDs located at the proximal descending aorta (HR: 2.95; 95% CI: 1.65-5.29; P &lt; 0.001) were associated with AAEs.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">CONCLUSIONS: Patients with FCE accompanying IMH were more likely to progress, especially in those initial FID localized at the proximal descending aorta. (Nature course and predictors of progression of intramural hematoma: A retrospective, multicenter study; ChiCTR2300073829).</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38267112/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240127211631&v=2.18.0">38267112</a> | DOI:<a href=https://doi.org/10.1016/j.jacc.2023.10.046>10.1016/j.jacc.2023.10.046</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38267112</guid>
<pubDate>Wed, 24 Jan 2024 06:00:00 -0500</pubDate>
<dc:creator>Xiaolang Jiang</dc:creator>
<dc:creator>Tianyue Pan</dc:creator>
<dc:creator>Yifan Liu</dc:creator>
<dc:creator>Bin Chen</dc:creator>
<dc:creator>Junhao Jiang</dc:creator>
<dc:creator>Daqiao Guo</dc:creator>
<dc:creator>Xin Xu</dc:creator>
<dc:creator>Kai Hou</dc:creator>
<dc:creator>Jiang Lin</dc:creator>
<dc:creator>Shuai Ju</dc:creator>
<dc:creator>Weiguo Fu</dc:creator>
<dc:creator>Zhihui Dong</dc:creator>
<dc:date>2024-01-24</dc:date>
<dc:source>Journal of the American College of Cardiology</dc:source>
<dc:title>Prognostic Implications of Initial Focal Contrast Enhancement in Acute Type B Intramural Hematoma</dc:title>
<dc:identifier>pmid:38267112</dc:identifier>
<dc:identifier>doi:10.1016/j.jacc.2023.10.046</dc:identifier>
</item>





























</channel>
</rss>